RESUMEN
We describe the case of a 60-year-old woman with chronic eosinophilic pneumonia (Carrington's disease) who developed symmetric rheumatoid factor-negative polyarthritis suggestive of rheumatoid arthritis. Although these two diseases are well documented as separate entities, 10 cases in the literature suggest possible links. However, the course in our patient raised the possibility of Churg-Strauss syndrome, a condition that may overlap with chronic eosinophilic pneumonia.
Asunto(s)
Artritis Reumatoide/epidemiología , Artritis Reumatoide/tratamiento farmacológico , Síndrome de Churg-Strauss/diagnóstico , Comorbilidad , Progresión de la Enfermedad , Femenino , Glucocorticoides/administración & dosificación , Humanos , Persona de Mediana Edad , Eosinofilia Pulmonar/diagnóstico , Eosinofilia Pulmonar/epidemiologíaRESUMEN
Trabectedin is a new marine-derived compound that binds the DNA minor groove and interacts with proteins of the DNA-repair machinery. Trabectedin has shown promising single-agent activity in pretreated patients with soft-tissue sarcoma (STS) and ovarian and breast cancer; combination with various other chemotherapeutic drugs is feasible. Toxicities are mainly hematological and hepatic, with grade 3-4 neutropenia and thrombocytopenia observed in approximately 50 and 20% of patients, respectively, and grade 3-4 elevation of liver transaminases observed in 35-50% of patients treated with trabectedin. Trabectedin obtained regulatory approval by the EMEA and in other countries for the treatment of STS patients after failure of all available standard-of-care chemotherapy. Current research focuses on the identification of predictive factors for patients treated with trabectedin as well as the development of other combinations.
